Trial Profile
Switch To RItuXimab in MS extension An extension study of STRIX-MS - a phase 2 open label study of Rituximab in MS patients previously treated with self-injectibles using a target based therapy approach
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Jun 2018
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms STRIX-MSext
- 21 Jun 2018 Status changed from recruiting to completed.
- 25 Apr 2018 New trial record